Table 4.
Plasma lipid changes induced by supplementary treatment with BBR/P/RR in 30 HeFH patients on stable-dose therapy with STs or STs plus EZE
| Lipid parameter | Baseline | on STs or STs + EZE | % changes vs baseline | plus BBR/P/RR | % changes after BBR/P/RR addition | P |
|---|---|---|---|---|---|---|
| TC (mmol/L) |
9.94 ± 1.49 |
6.35 ± 0.99† |
−35.5 ± 8.5 |
5.54 ± 0.77†‡ |
−43.7 ± 7.3 |
< 0.001 |
| LDL-C (mmol/L) |
7.91 ± 1.35 |
4.47 ± 0.94† |
−42.6 ± 10.9 |
3.65 ± 0.71†§ |
−53.2 ± 8.7 |
< 0.001 |
| HDL-C (mmol/L) |
1.29 ± 0.39 |
1.30 ± 0.35 |
+2.6 ± 10.3 |
1.33 ± 0.38 |
+4.3 ± 11.4 |
NS |
| non-HDL-C (mmol/L) |
8.65 ± 1.47 |
5.05 ± 1.06† |
−41.2 ± 9.8 |
4.20 ± 0.84†‡ |
−50.9 ± 8.7 |
< 0.001 |
| TG (mmol/L) | 1.48 (0.98-2.30) | 1.27 (0.89-2.03) | −17.7 ± 17.2 | 1.11 (0.83-1.63)* | −23.1 ± 21.2 | < 0.03 |
Values are means ± SD or medians (interquartile ranges). *P <0.05 vs baseline, †P < 0.02 vs baseline; ‡P < 0.05 vs STs and STs + EZE, §P < 0.02 vs STs and STs + EZE (ANOVA and multiple comparisons among pairs of means by t-tests with Bonferroni's correction). ¶P: significance of the differences between percent changes induced by STs or STs + EZE and those induced by treatment supplementation with BBR/P/RR (Student’s t test for paired data or Wilcoxon test). NS: not significant.